A Phase 2 Study of Revumenib in People With Acute Leukemia

Full Title

Purpose

Researchers want to see how well revumenib works against acute leukemia. The people in this study have acute leukemia that keeps growing after treatment. They also have a mutation (change) in the HOX gene, which is related to new or immature leukemia cells.

Revumenib is designed to block a protein called menin, which is required for leukemia cells to divide. By blocking menin, revumenib may prevent cancer cells from growing, and your cancer may stop spreading or may shrink. Revumenib is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have acute leukemia that keeps growing after treatment and has a HOX mutation.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 12 or older.

Contact

For more information or to see if you can join this study, please call Dr. Eytan Stein’s office at 646-608-3749.